


Docket No. 17120FWCCON6 (AP) 2
Serial No. 10/621,195

In the Claims:

1. (Original) A method of treating ocular hypertension which comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula II:



wherein the hatched segments represent α bonds, the solid triangle represents a β bond, wavy line attachments indicate either the alpha (α) or beta (β) configuration; dashed bonds represent a double bond or a single bond, R is a substituted hetero aryl radical, R¹ is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of -OR¹, -N(R¹)₂, and -N(R⁵)SO₂R⁶, wherein R⁵ represents hydrogen or CH₂OR⁶ and R⁶ represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is =O or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.


2. (Original) The method of Claim 1 wherein the substituent on the heteroaryl radical is selected from the group consisting of lower alkyl, halogen, trifluoromethyl, COR₁, COCF₃, SO₂NR₁, SO₂NH₂, NO₂ and CN.

3. (Original) A pharmaceutical product, comprising a container adapted to dispense the contents of said container in metered form; and an ophthalmic

Docket No. 17120FWCCON6 (AP) 3
Serial No. 10/621,195

solution in said container comprising a compound of formula I as defined in Claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle.

4. (Original) A method of treating glaucoma which comprises administering to a mammal having glaucoma a therapeutically effective amount of a compound represented by formula I:




wherein the wavy segments represent either an alpha (α) or beta (β) bond; dashed bonds represent a double bond or a single bond, R is a substituted hetero aryl radical, R¹ is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of -OR¹, -N(R¹)₂, R¹ is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of -OR¹, -N(R¹)₂, and -N(R⁵)SO₂R⁶, wherein R⁵ represents hydrogen or CH₂OR⁶ and R⁶ represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is =O or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.

Docket No. 17120FWCCON6 (AP) 4


Serial No. 10/621,195

5. (Original) The method of claim 4 wherein said compound is represented by formula II:



wherein the hatched segments represent α bonds and the triangular segment represents a β bond.

6. (Original) A method of treating elevated intraocular pressure which comprises administering to a mammal having elevated intraocular pressure a therapeutically effective amount of a compound represented by formula I:




wherein the wavy segment represents either an α or β bond; dashed bonds represent a double bond or a single bond, R is a substituted hetero aryl

Docket No. 17120FWCCON6 (AP) 5

Serial No. 10/621,195

radical, R^1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of $-OR^1$, $-N(R^1)_2$, R^1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of $-OR^1$, $-N(R^1)_2$, and $-N(R^5)SO_2R^6$, wherein R^5 represents hydrogen or CH_2OR^6 and R^6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is $=O$ or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.

7. (Original) The method of claim 6 wherein said compound is represented by formula II:



wherein the hatched segments represent α bonds and the triangular segment represents a β bond.